# MOTS-c: Research Overview — nuupeptide

> A literature summary of MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c), a mitochondrial-derived peptide studied for insulin sensitivity, skeletal muscle, aging and exercise biology.

Encoded inside the mitochondrial genome rather than the nuclear one — and studied as an exercise-mimetic regulator of metabolic aging in skeletal muscle.

## The short version

MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR. What makes it unusual is where its gene lives: not in the nuclear genome, where nearly all human proteins are encoded, but inside the mitochondria themselves — specifically within the 12S ribosomal RNA gene of the mitochondrial DNA. For most of the history of molecular biology, that region was not thought to encode functional proteins. MOTS-c overturned that assumption [10].

Its primary action is to activate AMPK — a master energy sensor — by inhibiting the folate cycle and de novo purine biosynthesis, which triggers AMPK's perception of energy stress. In aged mice, injected MOTS-c significantly enhanced physical performance — running capacity, grip strength, gait — compared to untreated aged animals [11]. Under metabolic stress it moves from the mitochondrion to the cell nucleus and regulates the expression of antioxidant and metabolic genes [12].

The honest limits: every claim about exogenous MOTS-c improving human metabolism, performance, or aging comes from cell or animal studies. Human data consist of biomarker *associations*, not intervention outcomes. MOTS-c is not approved by the FDA for any use, is sold only for laboratory research, and this page gives no dose or administration protocol.

## What it is

MOTS-c is a mitochondrial-derived peptide (MDP) — a class of molecules only recognized in the last decade or so, arising from previously overlooked short open reading frames within the mitochondrial genome. Its specific gene sits within the MT-RNR1 gene (the 12S ribosomal RNA gene), and the peptide is highly conserved across mammalian species, suggesting meaningful evolutionary function.

The full name — Mitochondrial Open Reading Frame of the 12S rRNA type-c — is descriptive of its origin rather than its function. The 16-amino-acid sequence MRWQEMGYIFYPRKLR encodes a peptide that is produced in the mitochondrion and, under basal conditions, operates there; under metabolic stress it moves. That intracellular translocation, from mitochondrion to nucleus, is one of the defining features of MOTS-c biology that distinguishes it from most mitochondrial proteins [12].

The research-chemical context: MOTS-c is available from laboratory chemical suppliers for research use only. It is not an approved medicine, there is no validated human formulation, and its purity and sterility in commercially available preparations vary by supplier and are not regulated as pharmaceuticals.

## How it works

MOTS-c's mechanism has been progressively clarified across several studies, and the picture is now reasonably detailed at the cell and animal level:

**Primary metabolic action.** MOTS-c inhibits the folate cycle and de novo purine biosynthesis. That inhibition leads to an accumulation of AICAR (an AMP-kinase-activating intermediate), which activates AMP-activated protein kinase (AMPK). AMPK is a cellular energy sensor that, when activated, promotes glucose uptake in skeletal muscle, fatty acid oxidation, and mitochondrial biogenesis — effects that overlap substantially with what exercise produces [10].

**Nuclear translocation.** Under metabolic stress, MOTS-c translocates from the mitochondrion to the nucleus. Once there, it works in an AMPK-dependent manner to regulate nuclear gene expression, including antioxidant-response-element (ARE) genes through interaction with NRF2 (NFE2L2). This was the first demonstrated example of a mitochondria-encoded peptide exerting retrograde gene regulation — sending a signal back from the mitochondrion to the nuclear genome [12].

**Direct molecular target.** A 2024 study using cell-free assays identified casein kinase 2 (CK2) as a direct binding target of MOTS-c — not just a downstream effector but a molecule the peptide physically engages. In mice, tissue-specific CK2 modulation (activation in muscle, suppression in fat) was shown to underlie MOTS-c's effects on muscle glucose uptake and atrophy prevention [8].

**Exercise inducibility.** Endogenous MOTS-c rises in skeletal muscle and circulation with exercise, which has led researchers to propose it as an exercise-induced mitokine — a hormone-like signal that translates the metabolic effects of physical activity into systemic responses. This is the basis for the "exercise-mimetic" framing, though that framing requires caution: mimicking a signal is not identical to the full physiological response to exercise [11].

## What the research shows

**Physical performance in aged mice.** In 2021, MOTS-c was given to mice at 2, 12, and 22 months of age, representing young, middle-aged, and old animals. Exogenous MOTS-c significantly increased treadmill running capacity (p=0.000002 in aged animals), grip strength, and gait in old mice. The study also established that endogenous MOTS-c is induced by exercise in skeletal muscle and circulation across all age groups. The authors positioned MOTS-c as "an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis" [11].

**Skeletal muscle function via CK2.** The 2024 study establishing CK2 as a direct target showed that MOTS-c prevented skeletal muscle atrophy in immobilized mice and enhanced muscle glucose uptake in high-fat-diet animals, effects mediated through tissue-specific CK2 activation in muscle and CK2 suppression in fat. The cell-free binding assays confirmed direct physical interaction between MOTS-c and CK2, moving the mechanism from correlation to direct molecular contact [8].

**Nuclear translocation and gene regulation.** Cell studies in HEK293 and fibroblast lines showed that under metabolic stress (metformin, glucose withdrawal), MOTS-c moves to the nucleus and activates ARE genes through NRF2 interaction in an AMPK-dependent manner. Blocking AMPK blocked the nuclear translocation effect. This retrograde signaling — mitochondrion sending a peptide to regulate the nuclear genome — was the first of its kind described [12].

**Human clinical association: mortality and cardiovascular risk.** A prospective multicenter cohort study in 94 chronic hemodialysis patients (median 26.5-month follow-up) found that circulating MOTS-c was independently associated with a composite endpoint of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05), and that adding MOTS-c to the risk model improved ROC discrimination (AUC 0.727 → 0.743). This is the strongest human data for MOTS-c, and it is an *observational association* — lower circulating MOTS-c tracks with worse outcomes, not a demonstration that exogenous MOTS-c changes those outcomes [9].

**The 2023 comprehensive review.** A 2023 review in the *Journal of Translational Medicine* synthesized MOTS-c biology across mechanism, stress adaptation, metabolism, and aging pathways — covering its encoding within MT-RNR1, the AMPK/folate-cycle mechanism, nuclear translocation, exercise inducibility, and metabolic roles [10]. This is the modern reference document for MOTS-c research.

## Reported effects, cautions & safety

MOTS-c's caution profile is shaped by the early stage of its evidence base:

**No human efficacy trials.** Every claim about exogenous MOTS-c improving metabolism, performance, or aging in humans derives from animal experiments or observational biomarker studies. No interventional human efficacy trials have been published [9][10]. The hemodialysis cohort finding is an association, not a causal demonstration.

**No validated human pharmacokinetics.** There is no published measured human half-life, bioavailability, or dose-response for MOTS-c. Rodent doses used in studies (ranging from roughly 0.5 to 15 mg/kg per day, depending on the study) cannot be extrapolated to humans, and this site does not offer any dosing guidance.

**Anti-doping status.** MOTS-c is treated as a prohibited substance in elite sport. Anti-doping bodies including USADA and WADA classify MOTS-c among peptide and metabolic-modulator agents prohibited at all times; athlete use can result in sanctions. This is a concrete concern for any competitive or tested athlete considering research use [9].

**Research-chemical supply.** MOTS-c is sold by chemical suppliers for laboratory research only; product purity, identity, and sterility are not regulated as pharmaceuticals and vary by supplier.

**Ancestry and genotype variation.** A pro-diabetogenic MOTS-c mtDNA variant (m.1382A>C) and ancestry-dependent exercise responses have been described in the literature, suggesting that MOTS-c effects are not uniform across populations [10].

**Small-sample and single-lab reliance.** Several mechanistic and human biomarker studies are small or preliminary; some findings await independent replication in larger or more diverse cohorts.

*This site's source material does not include compiled community-anecdote reports for MOTS-c; the cautions above are drawn from the cited peer-reviewed literature.*

## Where it fits in cellular-energy research

MOTS-c is the mitochondrion's own voice on this desk — a peptide that the cell's energy-generating organelle writes and sends when metabolic stress demands a response. Its story is the newer of the two covered here: it was only described in 2015, and the field is still mapping its mechanism and reach. Where [NAD+](/nad) is the established coenzyme central to energy metabolism and aging across all cell types, MOTS-c is an emerging signal that emerges specifically from the mitochondria, in response to the metabolic state that NAD+ metabolism reflects.

The two are not alternative approaches to the same thing — they are different layers of the same biology, and reading them together gives a richer picture than either alone. See the [comparison page](/compare) for the side-by-side.

![MOTS-c mitochondria-encoded peptide signaling in cold azure graphite palette](/images/mots-c.webp)

---

An independent literature digest on the cellular energy of aging — citations first, commerce last, conclusions honest.